GlassScriptPhysician profile
Anne Z Boteler
NPI 1477287688
$1,441.22
in general payments reported to CMS, 2019-2025
22 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 89% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $279 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $166.08 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $134.91 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $119.85 | 2025 | Auvelity |
| Gilead Sciences, INC. | $119.78 | 2024 | Epclusa |
| Pfizer INC. | $115.59 | 2025 | |
| Lilly USA, LLC | $114.00 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $93.22 | 2025 | Wegovy, Ozempic, Rybelsus |
| Lundbeck LLC | $81.32 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $80.03 | 2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $54.94 | 2024-2025 | Airsupra |
| Sumitomo Pharma America, INC. | $51.00 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.65 | 2024-2025 | Xifaxan |
| Abiomed | $41.86 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.55 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $29.24 | 2025 | Korlym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $28.44 | 2024 | Injectafer |
| Alexion Pharmaceuticals, INC. | $28.28 | 2025 | Koselugo |
| Shield Therapeutics INC | $24.13 | 2025 | |
| Phathom Pharmaceuticals, INC. | $23.13 | 2025 | Voquezna |
| Exact Sciences Corporation | $19.49 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $19.45 | 2025 | Shingrix |
| Astellas Pharma US INC | $17.28 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Boteler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.